Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.

Revenue projections:

Revenue projections for CAPLIPOINT
Revenue projections for CAPLIPOINT

Revenues for Caplin Point Laboratories Limited are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 6.965000
forwardPE 20.157843
debtToEquity 0.174000
earningsGrowth 0.175000
revenueGrowth 0.104000
grossMargins 0.602140
operatingMargins 0.300570
trailingEps 70.220000
forwardEps 0.000000

The current ratio for CAPLIPOINT is 6.965, indicating that the company can service its short-term debt using available cash and assets. This suggests CAPLIPOINT has strong liquidity, with more than enough resources to meet its immediate financial commitments.
CAPLIPOINT's Forward PE ratio is favorable, indicating that the stock price is well-positioned in relation to its earnings. It is not overpriced, leaving room for growth, which makes it a solid option for investors seeking both stability and future appreciation.
With positive growth in both earnings and revenue, CAPLIPOINT is expected to grow its business. These indicators highlight a strong financial outlook, with the company on track for continued expansion and increasing profitability.
With positive gross and operating margins, CAPLIPOINT demonstrates its profitability and efficiency. These metrics show that the company is managing costs well while generating strong revenue, highlighting robust financial health.

Price projections:

Price projections for CAPLIPOINT
Price projections for CAPLIPOINT



Recommendation changes over time:

Recommendations trend for CAPLIPOINT
Recommendations trend for CAPLIPOINT


Analysts' buy bias for Caplin Point Laboratories Limited signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to Caplin Point Laboratories Limited, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.